8-K: LifeVantage Caps Strong FY25 with Q4 Revenue Surge

LifeVantage Corporation reported robust financial results for its fourth fiscal quarter and full fiscal year 2025, driven by strong revenue growth in the Americas and a return to international expansion.

Summary

• Fourth quarter fiscal 2025 revenue increased 12.6% to $55.1 million, or 11.6% excluding foreign currency fluctuations, compared to the prior year period.
• Full fiscal year 2025 revenue grew 14.2% to $228.5 million, or 14.4% excluding foreign currency fluctuations, compared to fiscal 2024.
• Net income per diluted share for Q4 2025 was $0.15, up from $0.10 a year ago; for the full fiscal year 2025, it was $0.75, up from $0.23 in fiscal 2024.
• Adjusted EBITDA for the full fiscal year 2025 increased 30.3% to $22.1 million.
• The company repurchased 0.3 million shares for $3.1 million during fiscal 2025 and maintains a strong balance sheet with $20.2 million in cash and no debt as of June 30, 2025.
• International business (Asia/Pacific & Europe) returned to growth in Q4 2025, increasing 7.6% (1.6% constant currency), after a full-year decrease of 9.4%.
• Americas revenue showed strong growth, up 14.1% in Q4 2025 and 21.5% for the full fiscal year 2025.

Sentiment

Score: 8

Explanation: The company reported strong financial performance for both the quarter and the full fiscal year, with significant growth in revenue, net income, and adjusted EBITDA. The return to growth in international markets is a key positive, and the FY2026 guidance indicates continued optimism. While Q4 operating income was down, the overall trend and outlook are very positive.

Positives

• Strong revenue growth in Q4 2025 (12.6% to $55.1 million) and full fiscal year 2025 (14.2% to $228.5 million).
• Significant increase in net income per diluted share for both Q4 ($0.15 vs $0.10) and full year ($0.75 vs $0.23).
• Adjusted EBITDA for fiscal year 2025 increased by 30.3% to $22.1 million.
• International business in Asia/Pacific & Europe returned to growth in Q4 2025, increasing 7.6% (1.6% constant currency), for the first time in nearly three years.
• Continued strong performance in the Americas, with revenue growth of 14.1% in Q4 and 21.5% for the full fiscal year.
• Expanded gross margin for both Q4 (79.9% vs 79.5%) and full year (80.4% vs 79.3%), primarily due to favorable product mix and decreased inventory obsolescence costs.
• Strong balance sheet with $20.2 million of cash and no debt as of June 30, 2025.
• Declaration of a cash dividend of $0.045 per common share.
• Successful rollout of the MindBody System to Japan, Australia, Europe, and Thailand.
• Decrease in commissions and incentives as a percentage of revenue in Q4 (42.1% vs 44.9%) due to reduced incentive expenses.
• SG&A as a percentage of revenue decreased for the full year (30.3% vs 34.2%).

Negatives

• Adjusted EBITDA was flat in Q4 2025 at $4.8 million compared to the prior year period.
• Operating income decreased in Q4 2025 to $2.1 million from $2.9 million in Q4 2024.
• Adjusted operating income also decreased in Q4 2025 to $2.5 million from $3.2 million in Q4 2024.
• Cash generated from operations decreased slightly in fiscal 2025 to $11.9 million from $12.2 million in fiscal 2024.
• Commissions and incentives expense as a percentage of revenue increased for the full fiscal year (44.7% vs 42.9%) due to higher qualifications within existing promotional and incentive programs and changes in sales mix.
• SG&A expenses increased in Q4 2025 ($18.7 million vs $14.0 million) primarily due to costs related to the global convention and increases in variable employee compensation.
• Active Independent Consultants in Asia/Pacific & Europe decreased by 5.6% (1,000 accounts) as of June 30, 2025.
• Active Customers in Asia/Pacific & Europe decreased by 6.3% (1,000 accounts) as of June 30, 2025.
• Total Active Accounts in Asia/Pacific & Europe decreased by 5.9% (2,000 accounts) as of June 30, 2025.

Risks

• Potential for further deterioration to the global economic and operating environments, which could impact financial performance.
• The timing and amount of future dividends could vary significantly and are not assured.
• Forward-looking statements are not guarantees of performance and actual results could differ materially due to known and unknown risks and uncertainties.

Future Outlook

The company expects fiscal year 2026 revenue to be in the range of $225 million to $240 million, with adjusted EBITDA projected between $23 million and $26 million, and adjusted earnings per share anticipated to be $1.00 to $1.15. A full year tax rate of approximately 24% to 26% is also expected, reflecting current business trends and excluding non-operating or non-recurring expenses.

Management Comments

• Fourth quarter results capped off a strong fiscal 2025 as we delivered revenue growth of approximately 13% to $55.1 million, expanded gross margin and increased earnings.
• What's particularly exciting is that our international business returned to growth for the first time in nearly three years, with Asia/Pacific & Europe revenue increasing approximately 8% as we successfully rolled out our MindBody System to Japan, Australia, Europe, and Thailand.
• This international momentum, combined with continued strong performance in the Americas where revenue grew approximately 14%, demonstrates the global appeal of our activation-focused wellness solutions.
• As we enter fiscal 2026, we have built a powerful, scalable platform that positions us well for continued growth and long-term value creation.

Industry Context

LifeVantage operates in the health and wellness industry, specifically pioneering in nutrigenomics, which focuses on how nutrition and natural compounds activate genes for health. The company's direct selling model for 'activation-focused wellness solutions' positions it within a competitive market for dietary supplements and personal care products. The return to growth in international markets, particularly Asia/Pacific & Europe, suggests successful adaptation to regional market dynamics and product launches like the MindBody System, aligning with broader consumer trends towards personalized and preventative health.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks. Therefore, a direct assessment against industry-specific competitors or global standards cannot be made based solely on the provided information.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased earnings, share repurchases, and a declared cash dividend. The positive FY2026 guidance also suggests potential for future returns.
• Employees: Variable compensation expenses increased, suggesting potential for higher performance-based pay.
• Customers: Continued strong growth in active customers in the Americas, indicating product appeal.
• Independent Consultants: Growth in active consultants in the Americas, but a decline in Asia/Pacific & Europe. Increased commissions and incentives as a percentage of revenue for the full year suggests higher payouts for qualified consultants.

Next Steps

• Hold an investor conference call on September 4, 2025, at 2:30 p.m. MST (4:30 p.m. EST).
• Pay a cash dividend of $0.045 per common share on September 16, 2025.
• Continue executing on the current share repurchase program, with approximately $17.3 million remaining authorization.
• Focus on continued growth and long-term value creation in fiscal 2026, as per management's statements.

Key Dates

Recommendation

The company delivered robust financial results for fiscal year 2025, marked by significant revenue growth, substantial increases in net income and adjusted EBITDA, and a strong balance sheet with no debt. The return to growth in the international segment, particularly Asia/Pacific & Europe, after a multi-year decline, is a critical positive indicator of successful strategic execution and market penetration. The positive guidance for fiscal year 2026, projecting continued growth in key financial metrics, further reinforces a strong outlook. The ongoing share repurchase program and declared dividend demonstrate a commitment to returning value to shareholders. While Q4 operating income saw a slight dip, the overall trajectory and strategic momentum suggest a compelling investment opportunity for long-term value creation.

Keywords

LifeVantage, LFVN, Financial Results, Earnings, Q4 2025, FY 2025, Nutrigenomics, Health and Wellness, Direct Selling, Revenue Growth, EBITDA, Net Income, Share Repurchase, Dividend, Americas Market, Asia/Pacific & Europe Market, MindBody System, Cellular Health